Columbia and Missouri researchers develop 3D-printed living knee implant NOVAKnee
Updated
Updated · Livescience.com · Apr 25
Columbia and Missouri researchers develop 3D-printed living knee implant NOVAKnee
9 articles · Updated · Livescience.com · Apr 25
The NOVAKnee implant, composed of a biodegradable scaffold with stem-cell-derived bone and cartilage, has been tested in lab mice and will soon undergo large animal trials, with human trials targeted for 2028.
Supported by the federally funded NITRO project, NOVAKnee aims to address limitations of conventional metal and plastic knee implants, particularly for younger patients who face pain, limited mobility, and multiple surgeries.
Researchers are exploring both autologous and allogeneic cell sources and envision the technology as a potential platform for other joint replacements, though further studies are needed to determine ideal candidates and long-term outcomes.
With human trials slated for 2028, what major hurdles must this 'living knee' overcome?
Beyond knees, could this regenerative technology soon start rebuilding other joints in the body?
Could this 'living' 3D-printed knee make revision surgeries a thing of the past?
What are the hidden biological risks of growing a brand-new knee inside your own body?
How will a new federal mandate ensure this revolutionary knee implant remains affordable?
Transforming Knee Osteoarthritis Treatment: NOVAKnee’s $39M Preclinical Launch for Living Implants
Overview
The NOVAKnee project, backed by a $39 million ARPA-H contract awarded in April 2026, has entered preclinical testing with the goal of launching human trials by 2028. Developed by Columbia University, the technology uses a patient-specific, 3D-printed biodegradable scaffold combined with stem cells to regenerate living knee tissue, offering a promising alternative to traditional implants. This innovation addresses the growing osteoarthritis epidemic, which drives high demand for knee replacements that often require complex revisions. Despite its potential, challenges remain, including manufacturing scalability, high costs, insurance coverage barriers, and regulatory uncertainties, all of which impact the accessibility and future adoption of this transformative therapy.